ReviewJournal of tropical medicine2014
Strategies to overcome antileishmanial drugs unresponsiveness.
Review in Journal of tropical medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Neutrophil extracellular traps formation: effect of Leishmania major promastigotes and salivary gland homogenates of Phlebotomus papatasi in human neutrophil culture.BMC microbiology · 2024Article
- Arsenic exposure to mouse visceral leishmaniasis model through their drinking water linked to the disease exacerbation via modulation in host protective immunity: a preclinical study.Scientific reports · 2023Article
- Immunotherapy and immunochemotherapy in combating visceral leishmaniasis.Frontiers in medicine · 2023Review
- Macrophage targeting of nitazoxanide-loaded transethosomal gel in cutaneous leishmaniasis.Royal Society open science · 2022Article
- Challenges and Tools for In VitroPathogens (Basel, Switzerland) · 2021Review
- GC-MS screening and antiparasitic action ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021Article
- Risk factors for antimony treatment failure in American Cutaneous Leishmaniasis in Northwestern-Argentina.PLoS neglected tropical diseases · 2021Article
- Xenodiagnosis to address key questions in visceral leishmaniasis control and elimination.PLoS neglected tropical diseases · 2020Review
- Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis.Cell reports · 2020Article
- Leishmanicidal effects of amphotericin B in combination with selenium loaded on niosome againstJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2019Article
- Nigella sativa oil entrapped polycaprolactone nanoparticles for leishmaniasis treatment.IET nanobiotechnology · 2018Article
- Cloning, expression, purification and spectrophotometric analysis of lanosterol 14-alpha demethylase from Leishmania braziliensis (LbCYP51).Molecular biology reports · 2018Article
- Combined Strategies to Improve the Expression of Recombinant Sterol C24-Methyltransferase from Leishmania braziliensis in E. coli.Molecular biotechnology · 2018Article
- Evaluating drug resistance in visceral leishmaniasis: the challenges.Parasitology · 2018Review
- VOSalophen: a vanadium complex with a stilbene derivative-induction of apoptosis, autophagy, and efficiency in experimental cutaneous leishmaniasis.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2017Article
- Mahanine exerts in vitro and in vivo antileishmanial activity by modulation of redox homeostasis.Scientific reports · 2017Article
- Evaluation of Correlation between the In Vitro Susceptibility of Field Isolates ofJournal of arthropod-borne diseases · 2017Article
- Elimination of visceral leishmaniasis on the Indian subcontinent.The Lancet. Infectious diseases · 2016Review
- Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model.Biomaterials · 2016Article
- Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective.Infectious diseases of poverty · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In the absence of effective vector control measures and vaccines against leishmaniasis, effective chemotherapy remains the mainstay of treatment. As the armoury of antileishmanial drugs is limited, strategies should be made to target the emergence of drug resistance. The loss of efficacy of antimonials such as sodium stibogluconate in the Indian subcontinent which has been the mainstay of treatment for more than six decades has raised concern to save the other drugs. In the current review, we highlight various steps which could be implemented to halt the increasing unresponsiveness of drugs such as monitoring of therapy in the form of rational dosing and duration of treatment, understanding the mechanism of action of the drugs and drug resistance, identification of markers of resistance, distribution of drugs free of cost, evolution of effective combination therapy and immunotherapy, and proper management of HIV/VL coinfection and post-kala-azar dermal leishmaniasis (PKDL). Strong support from governmental agencies and local communities in the form of education and orientation programmes for feasibility of implementing these strategies and affordability within the context of their health systems is needed in controlling and preventing leishmaniasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.